

## Suggested Agenda for EURAMOS Investigators Meeting

COG Fall Meeting  
Wed 22-October-2008

Area for presentation	Presenter	Duration (mins)	Comments
Introduction & trial design	Neyssa Marina (Chair)	5	
Need for international collaboration in rare diseases (including registration rate)	Stefan Bielack	10	
Discussion		3	
European perspective on participating in EURAMOS-1	Sigbjorn Smeland	5	
North American perspective on participating in EURAMOS-1	Neyssa Marina	5	
Discussion		3	
Hurdles: Ethics and regulatory issues	Mark Bernstein	5	
Hurdles: European funding	Carole Moquin-Patthey	5	
Discussion		3	
Hurdles: Practical issues, common data and CDC role - EURAMOS-1 infrastructure	Matt Sydes	10	
Discussion		3	
Issues in consent & randomisation (including accrual rates)	Jeremy Whelan & Dorothe Carrle	10	
Discussion		3	
Spin-off studies: need for biology studies	Richard Gorlick	5	
Spin-off studies: need for quality of life studies	Gabi Caleminus/Andreas Wiener & Raj Nagarajam	5	
Discussion		3	
Specific issues in data: pathology, chemo doses, interferon	Mark Krailo	10	Move to CRA session?
<b>Discussion: Planning for the future: what might be next for other collaborations?</b>	Neyssa Marina & Stefan Bielack	20	
<i>Total</i>		<i>113</i>	

### Other topics:

Monitoring  
Deviation from protocol therapy & duration of interferon

Draft version  
23-Sep-2008

Matt Sydes  
Neyssa Marina  
Mark Krailo  
Disia Page